Our priority is to protect and aid the health and safety of our employees, our customers and their patients. That means ensuring our vital products are available when needed. It also means finding new and creative ways to support the frontline healthcare providers working tirelessly to address the COVID-19 pandemic.
Learn More
In a retrospective study of Medicare patients with cancer, patients treated with Voraxaze® had all of the following benefits compared to nonglucarpidase patients treated with dialysis (dialysis+) and nonglucarpidase patients with or without dialysis treatment (dialysis+/-), respectively1*:
*Utilizing Medicare inpatient claims data between 2010 and 2017, investigators compared outcomes and healthcare resource utilization between patients treated with Voraxaze® (n=30) and patients not treated with Voraxaze® (n=701), all of whom had experienced AKI secondary to inpatient chemotherapy.
Mean length of stay (LOS) among patients treated with Voraxaze® and the non-Voraxaze® groups1
Rates of mortality among patients treated with Voraxaze® and the non-Voraxaze® groups1
Voraxaze® patients treated within 3 days of admission (n=18) had shorter ICU and hospital LOS compared to Voraxaze® patients treated after 3 days (n=12).
| Early cohort | Late cohort | |
|---|---|---|
| Overall length of stay | 10.0 days | 21.7 days (P=0.002) |
| Length of hospital stay after Voraxaze® | 8.5 days | 14.6 days (P=0.057) |
| Length of ICU stay | 0.8 days | 8.9 days (P=0.020) |
Not every patient requires Voraxaze®, but experts have assembled recommendations to help guide treatment.
Explore the guidelines for the use and stocking of Voraxaze® so that you’re prepared in an emergency.